Urakami Koji
Takeda Pharmaceutical Company Limited, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan.
Curr Pharm Biotechnol. 2005 Jun;6(3):193-203. doi: 10.2174/1389201054022904.
A great number of pharmaceutical substances exist in crystalline solid-state. Because of the complexity of their chemical structure many different polymorphs of a given substance can exist. Polymorphic forms of solid pharmaceuticals influence not only their dissolution behavior, i.e. bioavailability but also their solid-state stability. It is well known that only one polymorphic form is thermodynamically stable and all other metastable forms will convert, eventually, to the more stable form. Hence it is essential to choose the most suitable polymorphic form in the early stage of pharmaceutical development. The following article reviews the recent applications of solution calorimetry that allows characterization of pharmaceutical polymorphs through accurate determination of enthalpy of solution. Each crystalline form possesses a defined enthalpy of solution, therefore solution calorimetry is used for the quantitative analysis of the desired polymorphic form and determination of enthalpy of transition corresponding to the difference in enthalpies of solution for a polymorphic pair. More recently this technique has been applied to the estimation of thermodynamic transition temperature, which is useful for the evaluation of thermodynamic stability relationships between polymorphs. This article will also describe the kinetics and thermodynamics of polymorphic transitions, from a metastable form to the thermodynamically stable form, through studies using ampoule-based isothermal microcalorimetry. Such studies are particularly useful when metastable forms are to be selected in order to enhance bioavailability. If the metastable form, or the pharmaceutical product containing it, can be shown to be sufficiently stable, it could then be used in a formulation where its therapeutic effects could be exploited.
大量药物物质以结晶固态形式存在。由于其化学结构的复杂性,给定物质可能存在许多不同的多晶型物。固体药物的多晶型形式不仅会影响其溶解行为,即生物利用度,还会影响其固态稳定性。众所周知,只有一种多晶型形式是热力学稳定的,所有其他亚稳形式最终都会转化为更稳定的形式。因此,在药物开发的早期阶段选择最合适的多晶型形式至关重要。以下文章综述了溶液量热法的最新应用,该方法可通过准确测定溶解焓来表征药物多晶型物。每种晶型都具有确定的溶解焓,因此溶液量热法用于所需多晶型形式的定量分析以及对应于多晶型对溶解焓差异的转变焓的测定。最近,该技术已应用于热力学转变温度的估算,这对于评估多晶型物之间的热力学稳定性关系很有用。本文还将通过基于安瓿的等温微量热法研究,描述从亚稳形式到热力学稳定形式的多晶型转变的动力学和热力学。当选择亚稳形式以提高生物利用度时,此类研究特别有用。如果亚稳形式或含有它的药物产品能够被证明足够稳定,那么它就可以用于能够发挥其治疗效果的制剂中。